David Lewin

David A. Lewin, Ph.D., has over fifteen years of business development , licensing, and marketing experience in life sciences at Yale Ventures. He has spent well over twenty years successfully managing scientifically-based business alliances with biotech and pharmaceutical leaders in the U.S., Europe, and Asia. He has scientific business expertise in pharmaceuticals, biomarkers, cell biology, genomics, and proteomics and in many disease areas. Dave has been instrumental in establishing Yale Ventures, including Kolltan Pharmaceuticals, Biohaven Pharmaceuticals, Inzyme Pharma, and Kleo Pharmaceuticals. Prior to his work at OCR, Dave was a group leader for CuraGen Corporation in Collaborative Research/Alliance Management and Biomarkers Discovery and Development.